查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1453897

至 2030 年精神分裂情绪障碍市场预测 - 按类型（药物和心理治疗）、原因、应用、最终用户和地理位置进行的全球分析

Schizoaffective Disorders Market Forecasts to 2030 - Global Analysis By Type (Medication and Psychotherapy), Cause, Application, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球分裂情感性疾患市场规模为 76 亿美元，预计到 2030 年将达到 107 亿美元，预测期内复合CAGR为 4.9%。分裂情感性疾患是一种慢性精神健康状况，其特征是精神分裂症症状（例如幻觉或妄想）和情绪障碍（例如忧郁或躁狂）的组合。患有分裂情感障碍的人通常会经历精神病时期，在此期间他们可能难以区分真实与虚假，并伴随严重的情绪障碍。治疗通常包括抗精神病药物、情绪稳定剂和心理治疗的组合，以控制症状和改善功能。

据世界卫生组织称，2018 年，全球有 9.7 亿人，即每八人中就有 1 人患有精神疾病，包括焦虑症和忧郁症。现在，全球约有 19.86% 的成年人患有精神疾病。

市场动态：

司机：

提高认识和诊断

提高市场意识和加强诊断对于及时介入和改善患者治疗效果至关重要。透过有针对性的教育活动，医疗保健专业人员可以更好地识别细微的症状，促进早期识别和适当的治疗策略。此外，社区外展计划可以使个人和家庭能够寻求帮助，减少耻辱并为受影响的人创造一个支持性的环境。

克制：

与精神疾病相关的耻辱

儘管人们的认识有所进步，但误解仍然存在，阻碍了接受和获得治疗。患有这种疾病的人经常面临社会排斥和歧视，阻碍他们融入社会和就业机会。这种耻辱不仅加剧了他们的心理困扰，还阻止他们寻求帮助，从而使孤立和未经治疗的症状陷入恶性循环。因此，这是阻碍市场成长的主要因素。

机会：

专注个人化医疗

个人化医疗在这种疾病的治疗领域具有巨大的前景。客製化的方法整合了遗传、神经生物学和环境因素，为传统的一刀切治疗带来了深刻的转变。精准医学使临床医生能够根据患者个别特征选择治疗方法，提高疗效并最大限度地减少不良反应。因此，这些都是推动市场成长的因素。

威胁：

治疗费用高

分裂情感性障碍的治疗带来了巨大的经济负担，费用往往达到过高的水平。这包括与药物、治疗、住院和持续精神护理相关的费用。此外，生产力和社会支持损失等间接成本进一步加剧了个人及其家庭的财务压力。因此，治疗分裂情感性疾患的高成本是阻碍市场成长的因素。

Covid-19 影响：

COVID-19 大流行对市场产生了重大影响，导致治疗取得和病患照护中断。封锁措施、医疗机构能力下降以及将资源优先用于 COVID-19 管理导致了分裂情感障碍患者的诊断、治疗启动和治疗调整的延迟。远距医疗已成为远距咨询的重要工具，但数位存取和护理品质方面的差距仍然存在。

预计心理治疗领域在预测期内将是最大的

预计心理治疗领域在预测期内将是最大的。心理治疗在分裂情感性疾患的治疗中发挥着至关重要的作用，提供了与药物治疗相结合的综合方法。认知行为治疗（CBT）、支持性治疗和居家治疗是常用的治疗方式。他们的目标是加强应对策略、改善社会功能并促进药物依从性。

医院部门预计在预测期内复合CAGR最高

预计医院部门在预测期内的CAGR最高。针对分裂情感障碍市场的医院为经历这种复杂心理健康状况的个人提供专门的护理。这些设施提供全面的服务，包括诊断、药物管理、治疗和支持计划，旨在满足分裂情感性疾患患者的独特需求。

占比最大的地区：

由于认识的提高、诊断技术的改进和治疗方案的进步，预计北美将在预测期内占据最大的市场份额。製药公司正在投资研发，推出针对精神病和情绪症状的新疗法，改善患者的治疗效果。此外，政府的支持性措施和医疗改革进一步推动市场扩张。

复合CAGR最高的地区：

预计亚太地区在预测期内的复合CAGR最高。该地区各国心理健康服务的可用性和可近性差异很大。政府有关精神卫生保健的政策和法规，包括为精神卫生服务提供资金以及支持新治疗方案的研究和开发，可能会对该地区的分裂情感性障碍治疗市场产生重大影响。

主要进展：

2024 年 1 月，雅培宣布美国食品药物管理局 (FDA) 已批准其背根神经节 (DRG) 刺激疗法 Proclaim(TM) DRG 神经刺激系统的扩展 MRI 标籤，该系统允许患者接受全身 MRI植入设备时进行扫描。

2023 年 9 月，雅培宣布已完成 Bigfoot Biomedical 的收购，该公司是为糖尿病患者开发智慧胰岛素管理系统的领导者。

我们的报告提供了什么：

  • 区域和国家层面的市场份额评估
  • 对新进入者的策略建议
  • 涵盖2021年、2022年、2023年、2026年及2030年的市场资料
  • 市场趋势（驱动因素、限制因素、机会、威胁、挑战、投资机会和建议）
  • 根据市场预测提出关键业务部门的策略建议
  • 竞争性景观美化绘製主要共同趋势
  • 公司概况，包括详细的策略、财务状况和最新发展
  • 反映最新技术进步的供应链趋势

免费客製化产品：

本报告的所有客户都将有权获得以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 个）
    • 关键参与者的 SWOT 分析（最多 3 个）
  • 区域细分
    • 根据客户的兴趣对任何主要国家的市场估计、预测和CAGR（註：取决于可行性检查）
  • 竞争基准化分析
    • 根据产品组合、地理分布和策略联盟对主要参与者基准化分析

目录

第 1 章：执行摘要

第 2 章：前言

  • 抽象的
  • 股东
  • 研究范围
  • 研究方法论
    • 资料探勘
    • 数据分析
    • 数据验证
    • 研究方法
  • 研究来源
    • 主要研究来源
    • 二手研究来源
    • 假设

第 3 章：市场趋势分析

  • 介绍
  • 司机
  • 限制
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • Covid-19 的影响

第 4 章：波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争竞争

第 5 章：全球分裂情感性疾患市场：依类型

  • 介绍
  • 药物
    • 情绪稳定剂
    • 抗精神病药
    • 抗忧郁药
  • 心理治疗
    • 个别治疗
    • 团体治疗

第 6 章：全球分裂情感性疾患市场：依原因分类

  • 介绍
  • 遗传因素
  • 环境因素
  • 化学因素

第 7 章：全球分裂情感性疾患市场：依应用分类

  • 介绍
  • 装置
  • 药品
  • 诊断
  • 其他应用

第 8 章：全球分裂情感性疾患市场：按最终用户

  • 介绍
  • 网路药房
  • 医院
  • 零售药房
  • 其他最终用户

第 9 章：全球分裂情感性疾患市场：依地理位置

  • 介绍
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太地区其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿联酋
    • 卡达
    • 南非
    • 中东和非洲其他地区

第 10 章：主要进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 扩充
  • 其他关键策略

第 11 章：公司概况

  • Abbott Pharmaceuticals
  • AstraZeneca PLC
  • Bright Quest
  • Bristol Myers Squibb
  • Cascade Behavioural Health Hospital
  • Ciba Pharmaceuticals
  • Cleveland Clinic
  • Covington Behavioural Health Hospital
  • Delta Medical Center
  • Elan Pharmaceuticals
  • Eli Lilly and Company
  • Janssen cilag Pvt. Ltd.
  • Johnson and Johnson
  • Merz Pharma GmbH & Co.
  • Pfizer
Product Code: SMRC25449

According to Stratistics MRC, the Global Schizoaffective Disorders Market is accounted for $7.6 billion in 2023 and is expected to reach $10.7 billion by 2030 growing at a CAGR of 4.9% during the forecast period. Schizoaffective disorder is a chronic mental health condition characterized by a combination of symptoms of schizophrenia, such as hallucinations or delusions, and mood disorders, such as depression or mania. Individuals with schizoaffective disorder typically experience periods of psychosis, during which they may have difficulty distinguishing between what is real and what is not, along with significant mood disturbances. Treatment usually involves a combination of antipsychotic medications, mood stabilizers, and psychotherapy to manage symptoms and improve functioning.

According to WHO, in 2018, 970 million individuals worldwide, or 1 in every eight persons, had a mental illness, including anxiety and depressive disorders. Now, around 19.86% of adults are experiencing a mental illness worldwide.

Market Dynamics:

Driver:

Increasing awareness and diagnosis

Raising awareness and enhancing diagnosis in the market is crucial for timely intervention and improved patient outcomes. Through targeted educational campaigns, healthcare professionals can better recognize the nuanced symptoms, facilitating early identification and appropriate treatment strategies. Additionally, community outreach programs can empower individuals and families to seek help, reducing stigma and fostering a supportive environment for those affected.

Restraint:

Stigma associated with mental illness

Despite strides in awareness, misconceptions persist, hindering acceptance and access to treatment. Individuals with this disorder often face social ostracization and discrimination, impeding their integration into society and employment opportunities. This stigma not only exacerbates their psychological distress but also deters them from seeking help, perpetuating a cycle of isolation and untreated symptoms. Thus, this is the major factor impeding the growth of the market.

Opportunity:

Focus on personalized medicine

Personalized medicine holds immense promise in the treatment landscape of this disorder. Tailored approaches, integrating genetic, neurobiological, and environmental factors, offer a profound shift from traditional one-size-fits-all treatments. Precision medicine enables clinicians to select therapies based on individual patient characteristics, enhancing efficacy and minimizing adverse effects. Hence, these are the factors propelling the growth of the market.

Threat:

High cost of treatment

The treatment of schizoaffective disorder presents significant financial burdens, with costs often reaching exorbitant levels. This encompasses expenses related to medication, therapy, hospitalizations, and ongoing psychiatric care. Additionally, indirect costs such as lost productivity and social support further escalate the financial strain on individuals and their families. Therefore, the high cost of managing schizoaffective disorder is the factor hampering the growth of the market.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the market, causing disruptions in treatment access and patient care. Lockdown measures, reduced healthcare facility capacities, and prioritization of resources towards COVID-19 management led to delays in diagnosis, treatment initiation, and therapy adjustments for schizoaffective disorder patients. Telehealth emerged as a vital tool for remote consultations, but disparities in digital access and quality of care persisted.

The psychotherapy segment is expected to be the largest during the forecast period

The psychotherapy segment is expected to be the largest during the forecast period. Psychotherapy plays a crucial role in the management of Schizoaffective Disorder, offering a comprehensive approach alongside medication. Cognitive-behavioral therapy (CBT), supportive therapy, and family therapy are commonly utilized modalities. They aim to enhance coping strategies, improve social functioning, and facilitate medication adherence.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is expected to have the highest CAGR during the forecast period. Hospitals catering to the Schizoaffective Disorders market offer specialized care tailored to individuals experiencing this complex mental health condition. These facilities provide comprehensive services, including diagnosis, medication management, therapy, and support programs, aimed at addressing the unique needs of patients with schizoaffective disorders.

Region with largest share:

North America is projected to hold the largest market share during the forecast period driven by increasing awareness, improved diagnostic techniques, and advancements in treatment options. Pharmaceutical companies are investing in research and development to introduce novel therapies addressing both psychotic and affective symptoms, enhancing patient outcomes. Additionally, supportive government initiatives and healthcare reforms further propel market expansion.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The availability and accessibility of mental health services vary widely across countries in the region. Government policies and regulations regarding mental health care, including funding for mental health services and support for research and development of new treatment options, can significantly impact the market for schizoaffective disorder treatment in the region.

Key players in the market

Some of the key players in Schizoaffective Disorders market include Abbott Pharmaceuticals, AstraZeneca PLC, Bright Quest, Bristol Myers Squibb, Cascade Behavioural Health Hospital, Ciba Pharmaceuticals, Cleveland Clinic, Covington Behavioural Health Hospital, Delta Medical Center, Elan Pharmaceuticals, Eli Lilly and Company, Janssen cilag Pvt. Ltd., Johnson and Johnson, Merz Pharma GmbH & Co. And Pfizer.

Key Developments:

In January 2024, Abbott announced that the U.S. Food and Drug Administration (FDA) has approved expanded MRI labeling for its dorsal root ganglion (DRG) stimulation therapy, the Proclaim(TM) DRG neurostimulation system, which allows patients to receive full-body MRI scans while implanted with the device.

In September 2023, Abbott announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.

Types Covered:

  • Medication
  • Psychotherapy

Causes Covered:

  • Genetic Factors
  • Environmental Factors
  • Chemical Factors

Applications Covered:

  • Devices
  • Drugs
  • Diagnostics
  • Other Applications

End Users Covered:

  • Online Pharmacy
  • Hospitals
  • Retail pharmacy
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Schizoaffective Disorders Market, By Type

  • 5.1 Introduction
  • 5.2 Medication
    • 5.2.1 Mood stabilizers
    • 5.2.2 Antipsychotics
    • 5.2.3 Antidepressants
  • 5.3 Psychotherapy
    • 5.3.1 Individual Therapy
    • 5.3.2 Group Therapy

6 Global Schizoaffective Disorders Market, By Cause

  • 6.1 Introduction
  • 6.2 Genetic Factors
  • 6.3 Environmental Factors
  • 6.4 Chemical Factors

7 Global Schizoaffective Disorders Market, By Application

  • 7.1 Introduction
  • 7.2 Devices
  • 7.3 Drugs
  • 7.4 Diagnostics
  • 7.5 Other Applications

8 Global Schizoaffective Disorders Market, By End User

  • 8.1 Introduction
  • 8.2 Online Pharmacy
  • 8.3 Hospitals
  • 8.4 Retail pharmacy
  • 8.5 Other End Users

9 Global Schizoaffective Disorders Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Abbott Pharmaceuticals
  • 11.2 AstraZeneca PLC
  • 11.3 Bright Quest
  • 11.4 Bristol Myers Squibb
  • 11.5 Cascade Behavioural Health Hospital
  • 11.6 Ciba Pharmaceuticals
  • 11.7 Cleveland Clinic
  • 11.8 Covington Behavioural Health Hospital
  • 11.9 Delta Medical Center
  • 11.10 Elan Pharmaceuticals
  • 11.11 Eli Lilly and Company
  • 11.12 Janssen cilag Pvt. Ltd.
  • 11.13 Johnson and Johnson
  • 11.14 Merz Pharma GmbH & Co.
  • 11.15 Pfizer

List of Tables

  • Table 1 Global Schizoaffective Disorders Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Schizoaffective Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Schizoaffective Disorders Market Outlook, By Medication (2021-2030) ($MN)
  • Table 4 Global Schizoaffective Disorders Market Outlook, By Mood stabilizers (2021-2030) ($MN)
  • Table 5 Global Schizoaffective Disorders Market Outlook, By Antipsychotics (2021-2030) ($MN)
  • Table 6 Global Schizoaffective Disorders Market Outlook, By Antidepressants (2021-2030) ($MN)
  • Table 7 Global Schizoaffective Disorders Market Outlook, By Psychotherapy (2021-2030) ($MN)
  • Table 8 Global Schizoaffective Disorders Market Outlook, By Individual Therapy (2021-2030) ($MN)
  • Table 9 Global Schizoaffective Disorders Market Outlook, By Group Therapy (2021-2030) ($MN)
  • Table 10 Global Schizoaffective Disorders Market Outlook, By Cause (2021-2030) ($MN)
  • Table 11 Global Schizoaffective Disorders Market Outlook, By Genetic Factors (2021-2030) ($MN)
  • Table 12 Global Schizoaffective Disorders Market Outlook, By Environmental Factors (2021-2030) ($MN)
  • Table 13 Global Schizoaffective Disorders Market Outlook, By Chemical Factors (2021-2030) ($MN)
  • Table 14 Global Schizoaffective Disorders Market Outlook, By Application (2021-2030) ($MN)
  • Table 15 Global Schizoaffective Disorders Market Outlook, By Devices (2021-2030) ($MN)
  • Table 16 Global Schizoaffective Disorders Market Outlook, By Drugs (2021-2030) ($MN)
  • Table 17 Global Schizoaffective Disorders Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 18 Global Schizoaffective Disorders Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 19 Global Schizoaffective Disorders Market Outlook, By End User (2021-2030) ($MN)
  • Table 20 Global Schizoaffective Disorders Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 21 Global Schizoaffective Disorders Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 22 Global Schizoaffective Disorders Market Outlook, By Retail pharmacy (2021-2030) ($MN)
  • Table 23 Global Schizoaffective Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 24 North America Schizoaffective Disorders Market Outlook, By Country (2021-2030) ($MN)
  • Table 25 North America Schizoaffective Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 26 North America Schizoaffective Disorders Market Outlook, By Medication (2021-2030) ($MN)
  • Table 27 North America Schizoaffective Disorders Market Outlook, By Mood stabilizers (2021-2030) ($MN)
  • Table 28 North America Schizoaffective Disorders Market Outlook, By Antipsychotics (2021-2030) ($MN)
  • Table 29 North America Schizoaffective Disorders Market Outlook, By Antidepressants (2021-2030) ($MN)
  • Table 30 North America Schizoaffective Disorders Market Outlook, By Psychotherapy (2021-2030) ($MN)
  • Table 31 North America Schizoaffective Disorders Market Outlook, By Individual Therapy (2021-2030) ($MN)
  • Table 32 North America Schizoaffective Disorders Market Outlook, By Group Therapy (2021-2030) ($MN)
  • Table 33 North America Schizoaffective Disorders Market Outlook, By Cause (2021-2030) ($MN)
  • Table 34 North America Schizoaffective Disorders Market Outlook, By Genetic Factors (2021-2030) ($MN)
  • Table 35 North America Schizoaffective Disorders Market Outlook, By Environmental Factors (2021-2030) ($MN)
  • Table 36 North America Schizoaffective Disorders Market Outlook, By Chemical Factors (2021-2030) ($MN)
  • Table 37 North America Schizoaffective Disorders Market Outlook, By Application (2021-2030) ($MN)
  • Table 38 North America Schizoaffective Disorders Market Outlook, By Devices (2021-2030) ($MN)
  • Table 39 North America Schizoaffective Disorders Market Outlook, By Drugs (2021-2030) ($MN)
  • Table 40 North America Schizoaffective Disorders Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 41 North America Schizoaffective Disorders Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 42 North America Schizoaffective Disorders Market Outlook, By End User (2021-2030) ($MN)
  • Table 43 North America Schizoaffective Disorders Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 44 North America Schizoaffective Disorders Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 45 North America Schizoaffective Disorders Market Outlook, By Retail pharmacy (2021-2030) ($MN)
  • Table 46 North America Schizoaffective Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 47 Europe Stain-Resistant Fabric Market Outlook, By Country (2021-2030) ($MN)
  • Table 48 Europe Schizoaffective Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 49 Europe Schizoaffective Disorders Market Outlook, By Medication (2021-2030) ($MN)
  • Table 50 Europe Schizoaffective Disorders Market Outlook, By Mood stabilizers (2021-2030) ($MN)
  • Table 51 Europe Schizoaffective Disorders Market Outlook, By Antipsychotics (2021-2030) ($MN)
  • Table 52 Europe Schizoaffective Disorders Market Outlook, By Antidepressants (2021-2030) ($MN)
  • Table 53 Europe Schizoaffective Disorders Market Outlook, By Psychotherapy (2021-2030) ($MN)
  • Table 54 Europe Schizoaffective Disorders Market Outlook, By Individual Therapy (2021-2030) ($MN)
  • Table 55 Europe Schizoaffective Disorders Market Outlook, By Group Therapy (2021-2030) ($MN)
  • Table 56 Europe Schizoaffective Disorders Market Outlook, By Cause (2021-2030) ($MN)
  • Table 57 Europe Schizoaffective Disorders Market Outlook, By Genetic Factors (2021-2030) ($MN)
  • Table 58 Europe Schizoaffective Disorders Market Outlook, By Environmental Factors (2021-2030) ($MN)
  • Table 59 Europe Schizoaffective Disorders Market Outlook, By Chemical Factors (2021-2030) ($MN)
  • Table 60 Europe Schizoaffective Disorders Market Outlook, By Application (2021-2030) ($MN)
  • Table 61 Europe Schizoaffective Disorders Market Outlook, By Devices (2021-2030) ($MN)
  • Table 62 Europe Schizoaffective Disorders Market Outlook, By Drugs (2021-2030) ($MN)
  • Table 63 Europe Schizoaffective Disorders Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 64 Europe Schizoaffective Disorders Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 65 Europe Schizoaffective Disorders Market Outlook, By End User (2021-2030) ($MN)
  • Table 66 Europe Schizoaffective Disorders Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 67 Europe Schizoaffective Disorders Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 68 Europe Schizoaffective Disorders Market Outlook, By Retail pharmacy (2021-2030) ($MN)
  • Table 69 Europe Schizoaffective Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 70 Asia Pacific Schizoaffective Disorders Market Outlook, By Country (2021-2030) ($MN)
  • Table 71 Asia Pacific Schizoaffective Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 72 Asia Pacific Schizoaffective Disorders Market Outlook, By Medication (2021-2030) ($MN)
  • Table 73 Asia Pacific Schizoaffective Disorders Market Outlook, By Mood stabilizers (2021-2030) ($MN)
  • Table 74 Asia Pacific Schizoaffective Disorders Market Outlook, By Antipsychotics (2021-2030) ($MN)
  • Table 75 Asia Pacific Schizoaffective Disorders Market Outlook, By Antidepressants (2021-2030) ($MN)
  • Table 76 Asia Pacific Schizoaffective Disorders Market Outlook, By Psychotherapy (2021-2030) ($MN)
  • Table 77 Asia Pacific Schizoaffective Disorders Market Outlook, By Individual Therapy (2021-2030) ($MN)
  • Table 78 Asia Pacific Schizoaffective Disorders Market Outlook, By Group Therapy (2021-2030) ($MN)
  • Table 79 Asia Pacific Schizoaffective Disorders Market Outlook, By Cause (2021-2030) ($MN)
  • Table 80 Asia Pacific Schizoaffective Disorders Market Outlook, By Genetic Factors (2021-2030) ($MN)
  • Table 81 Asia Pacific Schizoaffective Disorders Market Outlook, By Environmental Factors (2021-2030) ($MN)
  • Table 82 Asia Pacific Schizoaffective Disorders Market Outlook, By Chemical Factors (2021-2030) ($MN)
  • Table 83 Asia Pacific Schizoaffective Disorders Market Outlook, By Application (2021-2030) ($MN)
  • Table 84 Asia Pacific Schizoaffective Disorders Market Outlook, By Devices (2021-2030) ($MN)
  • Table 85 Asia Pacific Schizoaffective Disorders Market Outlook, By Drugs (2021-2030) ($MN)
  • Table 86 Asia Pacific Schizoaffective Disorders Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 87 Asia Pacific Schizoaffective Disorders Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 88 Asia Pacific Schizoaffective Disorders Market Outlook, By End User (2021-2030) ($MN)
  • Table 89 Asia Pacific Schizoaffective Disorders Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 90 Asia Pacific Schizoaffective Disorders Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 91 Asia Pacific Schizoaffective Disorders Market Outlook, By Retail pharmacy (2021-2030) ($MN)
  • Table 92 Asia Pacific Schizoaffective Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 93 South America Schizoaffective Disorders Market Outlook, By Country (2021-2030) ($MN)
  • Table 94 South America Schizoaffective Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 95 South America Schizoaffective Disorders Market Outlook, By Medication (2021-2030) ($MN)
  • Table 96 South America Schizoaffective Disorders Market Outlook, By Mood stabilizers (2021-2030) ($MN)
  • Table 97 South America Schizoaffective Disorders Market Outlook, By Antipsychotics (2021-2030) ($MN)
  • Table 98 South America Schizoaffective Disorders Market Outlook, By Antidepressants (2021-2030) ($MN)
  • Table 99 South America Schizoaffective Disorders Market Outlook, By Psychotherapy (2021-2030) ($MN)
  • Table 100 South America Schizoaffective Disorders Market Outlook, By Individual Therapy (2021-2030) ($MN)
  • Table 101 South America Schizoaffective Disorders Market Outlook, By Group Therapy (2021-2030) ($MN)
  • Table 102 South America Schizoaffective Disorders Market Outlook, By Cause (2021-2030) ($MN)
  • Table 103 South America Schizoaffective Disorders Market Outlook, By Genetic Factors (2021-2030) ($MN)
  • Table 104 South America Schizoaffective Disorders Market Outlook, By Environmental Factors (2021-2030) ($MN)
  • Table 105 South America Schizoaffective Disorders Market Outlook, By Chemical Factors (2021-2030) ($MN)
  • Table 106 South America Schizoaffective Disorders Market Outlook, By Application (2021-2030) ($MN)
  • Table 107 South America Schizoaffective Disorders Market Outlook, By Devices (2021-2030) ($MN)
  • Table 108 South America Schizoaffective Disorders Market Outlook, By Drugs (2021-2030) ($MN)
  • Table 109 South America Schizoaffective Disorders Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 110 South America Schizoaffective Disorders Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 111 South America Schizoaffective Disorders Market Outlook, By End User (2021-2030) ($MN)
  • Table 112 South America Schizoaffective Disorders Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 113 South America Schizoaffective Disorders Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 114 South America Schizoaffective Disorders Market Outlook, By Retail pharmacy (2021-2030) ($MN)
  • Table 115 South America Schizoaffective Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 116 Middle East & Africa Schizoaffective Disorders Market Outlook, By Country (2021-2030) ($MN)
  • Table 117 Middle East & Africa Schizoaffective Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 118 Middle East & Africa Schizoaffective Disorders Market Outlook, By Medication (2021-2030) ($MN)
  • Table 119 Middle East & Africa Schizoaffective Disorders Market Outlook, By Mood stabilizers (2021-2030) ($MN)
  • Table 120 Middle East & Africa Schizoaffective Disorders Market Outlook, By Antipsychotics (2021-2030) ($MN)
  • Table 121 Middle East & Africa Schizoaffective Disorders Market Outlook, By Antidepressants (2021-2030) ($MN)
  • Table 122 Middle East & Africa Schizoaffective Disorders Market Outlook, By Psychotherapy (2021-2030) ($MN)
  • Table 123 Middle East & Africa Schizoaffective Disorders Market Outlook, By Individual Therapy (2021-2030) ($MN)
  • Table 124 Middle East & Africa Schizoaffective Disorders Market Outlook, By Group Therapy (2021-2030) ($MN)
  • Table 125 Middle East & Africa Schizoaffective Disorders Market Outlook, By Cause (2021-2030) ($MN)
  • Table 126 Middle East & Africa Schizoaffective Disorders Market Outlook, By Genetic Factors (2021-2030) ($MN)
  • Table 127 Middle East & Africa Schizoaffective Disorders Market Outlook, By Environmental Factors (2021-2030) ($MN)
  • Table 128 Middle East & Africa Schizoaffective Disorders Market Outlook, By Chemical Factors (2021-2030) ($MN)
  • Table 129 Middle East & Africa Schizoaffective Disorders Market Outlook, By Application (2021-2030) ($MN)
  • Table 130 Middle East & Africa Schizoaffective Disorders Market Outlook, By Devices (2021-2030) ($MN)
  • Table 131 Middle East & Africa Schizoaffective Disorders Market Outlook, By Drugs (2021-2030) ($MN)
  • Table 132 Middle East & Africa Schizoaffective Disorders Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 133 Middle East & Africa Schizoaffective Disorders Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 134 Middle East & Africa Schizoaffective Disorders Market Outlook, By End User (2021-2030) ($MN)
  • Table 135 Middle East & Africa Schizoaffective Disorders Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 136 Middle East & Africa Schizoaffective Disorders Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 137 Middle East & Africa Schizoaffective Disorders Market Outlook, By Retail pharmacy (2021-2030) ($MN)
  • Table 138 Middle East & Africa Schizoaffective Disorders Market Outlook, By Other End Users (2021-2030) ($MN)